Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | TSHR | P16473 | 5/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | PDE5A | O76074 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1062734 | 0.85 | TGFBR1 (0.50) | ALDH1A1TSHRMEN1KMT2APDE5A | |
| SCHEMBL1063667 | 0.76 | ATM (0.48) | ALDH1A1MEN1KMT2APDE5APOLB | |
| SCHEMBL21347889 | 0.76 | CYP1A2 (0.62) | CYP1A2CYP3A4CLK4ALDH1A1TSHR | |
| SCHEMBL1062607 | 0.75 | NPC1 (0.46) | CYP1A2MEN1KMT2APDE5ANPSR1 | |
| SCHEMBL3113342 | 0.75 | CYP1A2 (0.58) | CYP1A2CYP3A4CLK4ALDH1A1CYP2D6 | |
| SCHEMBL3579261 | 0.72 | ADORA2A (0.59) | MEN1KMT2APDE5ALMNAMAPT | |
| SCHEMBL5075468 | 0.72 | CFTR (0.63) | ALDH1A1NPSR1SLC6A3KDM4E | |
| SCHEMBL30843879 | 0.71 | CYP1A2 (0.62) | CYP1A2CYP3A4CLK4ALDH1A1TSHR | |
| SCHEMBL30804557 | 0.71 | CYP1A2 (0.62) | CYP1A2CYP3A4CLK4ALDH1A1TSHR | |
| SCHEMBL13272569 | 0.71 | CYP1A2 (0.62) | CYP1A2CYP3A4CLK4ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110008289-A1 | HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100099851-A1 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-7597884-B2 | Hyperglycosylated polypeptide variants and methods of use | ALIOS BIOPHARMA, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-2093235-A1 | Hyperglycosylated variants of interferon alfacon-1 | Alios Biopharma Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1789074-A4 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA INC (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1789074-A2 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | Alios Biopharma Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20060204473-A1 | Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same | ALIOS BIOPHARMA, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060182716-A1 | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same | ALIOS BIOPHARMA, INC. | 2006-08-17 | — | — | US | disclosed |
| WO-2006020580-A2 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2005110455-A2 | COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTION | INTERMUNE, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2004105684-A2 | COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS | INTERMUNE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099851-A1 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | IFNAR1, IDE, CTSC | CYP1A2 1171/4885CYP3A4 267/4885CLK4 2917/4885 |
| US-20110008289-A1 | HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE | IFNAR1, EPOR, HBB | CYP1A2 834/4885CYP3A4 278/4885CLK4 3842/4885 |
| US-20060182716-A1 | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same | IFNAR1, IDE, CTSC | CYP1A2 1171/4885CYP3A4 267/4885CLK4 2917/4885 |
| US-20060204473-A1 | Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same | IFNAR1, EPOR, HBB | CYP1A2 924/4885CYP3A4 353/4885CLK4 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.